Targeted suppression of MCT-1 attenuates the malignant phenotype through a translational mechanism

Leuk Res. 2009 Mar;33(3):474-82. doi: 10.1016/j.leukres.2008.08.012. Epub 2008 Sep 27.

Abstract

The MCT-1 oncogene, highly expressed in a subset of non-Hodgkin's lymphomas interacts with the cap complex through its PUA domain. MCT-1 recruits DENR, a SUI1 motif containing protein that promotes translation initiation of cancer-related mRNAs. We reasoned that a PUA-domain mutant protein would repress MCT-1 function and attenuate the malignant phenotype. Human lymphoma cell lines expressing the PUA-domain mutant protein demonstrated reduced anchorage-independent growth and increased susceptibility to apoptosis. Significantly, we identified an altered translational profile in cells expressing the mutant protein. These data further buttress the role of the MCT-1 in lymphomagenesis and support the development of novel therapeutic strategies targeting MCT-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects
  • Cell Cycle Proteins / antagonists & inhibitors*
  • Cell Cycle Proteins / physiology
  • Cell Line, Tumor
  • Drug Delivery Systems
  • Eukaryotic Initiation Factors / metabolism
  • Humans
  • Lymphoma / drug therapy*
  • Lymphoma / etiology
  • Mutant Proteins / metabolism
  • Mutant Proteins / pharmacology
  • Mutant Proteins / therapeutic use
  • Neoplasm Proteins / biosynthesis
  • Oncogene Proteins / antagonists & inhibitors*
  • Oncogene Proteins / physiology
  • Protein Biosynthesis / drug effects*

Substances

  • Cell Cycle Proteins
  • DENR protein, human
  • Eukaryotic Initiation Factors
  • MCTS1 protein, human
  • Mutant Proteins
  • Neoplasm Proteins
  • Oncogene Proteins